PENKA, Miroslav, Jana MICHALCOVÁ, Jiřina ZAVŘELOVÁ, Marie PRUDKOVÁ and Alena BULIKOVÁ. Idarucizumab (Praxbind®) – studie RE-VERSE AD (Idarucizumab (Praxbind®) – the RE-VERSE AD study). Hypertenze & kardiovaskulární prevence. Praha: TARGED - MD, 2016, vol. 5, No 1, p. 54-60. ISSN 1805-4129.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Idarucizumab (Praxbind®) – studie RE-VERSE AD
Name (in English) Idarucizumab (Praxbind®) – the RE-VERSE AD study
Authors PENKA, Miroslav (203 Czech Republic, belonging to the institution), Jana MICHALCOVÁ (203 Czech Republic, guarantor, belonging to the institution), Jiřina ZAVŘELOVÁ (203 Czech Republic, belonging to the institution), Marie PRUDKOVÁ (203 Czech Republic) and Alena BULIKOVÁ (203 Czech Republic, belonging to the institution).
Edition Hypertenze & kardiovaskulární prevence, Praha, TARGED - MD, 2016, 1805-4129.
Other information
Original language Czech
Type of outcome Article in a journal
Field of Study 30200 3.2 Clinical medicine
Country of publisher Czech Republic
Confidentiality degree is not subject to a state or trade secret
RIV identification code RIV/00216224:14110/16:00092305
Organization unit Faculty of Medicine
Keywords (in Czech) trombin; inhibitor; antidotum; idarucizumab; RE-VERSE AD
Keywords in English thrombin; inhibitor; antidote; idarucizumab; RE-VERSE AD
Tags EL OK
Changed by Changed by: Soňa Böhmová, učo 232884. Changed: 13/12/2016 15:18.
Abstract
Nedávné zavedení idarucizumabu jako specifického antidota pro dabigatran do klinické praxe znamená významný pokrok v bezpečnosti antitrombotické léčby. Studie RE-VERSE AD potvrdila účinnost a bezpečnost idarucizumabu pro antagonizaci dabigatranu.
Abstract (in English)
The recent introduction of idarucizumab as specific antidote for dabigatran to clinical practice represents an important progress in safety of antithrombotic therapy. The RE-VERSE AD study confirmed the efficacy and safety of idarucizumab for dabigatran reversal.
PrintDisplayed: 28/5/2024 18:26